



Molecular and Cellular Changes in the Formation of Tumor-Initiating Cells

Guest Editor:

Dr. Zhe Li

1. Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
2. Division of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA

Deadline for manuscript submissions:

closed (30 September 2023)

Message from the Guest Editor

Tumor-Initiating Cells (TICs), also known as Cancer Stem Cells, refer to a subset of cancer cells capable of self-renewal proliferation and producing all other cancer cell types within a tumor. The concept of TICs is originally a functional definition, largely based on transplantation assays. The term TICs is now more widely used in cancer biology, often referring to or overlapping with cellular origin of cancer, most recent common ancestor of cancer (based on sequencing data), cancer cells with stem cell-like properties, therapy-resistant cancer cells, or metastasis-initiating cells. Nevertheless, TICs represent a key subset of cancer cells responsible for cancer initiation, progression, metastasis, and therapy resistance; therefore, a better mechanistic understanding of their formation would be essential for developing novel strategies of cancer prevention and therapy, and for overcoming therapy resistance.

The purpose of this Special Issue is to define molecular and cellular changes leading to the formation of TICs.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)